Anoat Therapeutics Overview
- Year Founded
-
2023
- Status
-
Out of Business
- Latest Deal Type
-
Liquidation
Anoat Therapeutics General Information
Description
Developer of novel therapies designed to transform the lives of patients with rare diseases. The company specializes in bringing a transformative and mutation-agnostic treatment option to cystic fibrosis patients for whom existing therapies are not effective, enabling clinicians to treat the life-threatening condition.
Contact Information
Corporate Office
- 4 Rue Thénard
- 75005 Paris
- France
Corporate Office
- 4 Rue Thénard
- 75005 Paris
- France
Anoat Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Bankruptcy: Liquidation | 03-Jan-2025 | Completed | Bankruptcy: Liquidation | |||
| 1. Seed Round | 16-May-2023 | Completed | Pre-Clinical Trials |
Anoat Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Anoat Therapeutics FAQs
-
When was Anoat Therapeutics founded?
Anoat Therapeutics was founded in 2023.
-
Where is Anoat Therapeutics headquartered?
Anoat Therapeutics is headquartered in Paris, France.
-
What industry is Anoat Therapeutics in?
Anoat Therapeutics’s primary industry is Drug Discovery.
-
Is Anoat Therapeutics a private or public company?
Anoat Therapeutics is a Private company.
-
What is Anoat Therapeutics’s current revenue?
The current revenue for Anoat Therapeutics is .
-
How much funding has Anoat Therapeutics raised over time?
Anoat Therapeutics has raised $2.2M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
